References
- Hornung RL, Longo DL, Bowersox OC, Kwak LW. Tumor antigen-specific immunization of bone marrow transplanta-tion donors as adoptive therapy against established tumor. yNatl Cancer Inst 1995;87:1289–96.
- Armitage JO. Bone marrow transplantation. N Engl y Med1994;330:827–38.
- Gilliland DG, Gribben JG. Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation. Biol Blood Marrow Transplant 2002;8:9–16.
- Maloney DG. Antibody therapy has arrived. Now where does it fit? Ann Oncol 1999;10:619–21.
- Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29:2–9.
- Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the com-bination of chimeric anti-C D20 monoclonal antibody and CHOP chemotherapy. y Clin Oncol 1999;17:268–76.
- Czuczman MS, Fallon A, Mohr A et al. Rituximab in com-bination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002;29:36–40.
- Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. y Clin Oncol 1998;16:2817–24.
- Schultze JL, Cardoso AA, Seamon MJ et al. Most follicularlymphomas do not stimulate an allogeneic T cell prolifera-tive response. Blood 1994;84:521a.
- Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40—dependent signal..7Exp Med 1993;177:925–35.
- Schultze JL, Cardoso AA, Freeman GJ et al. Follicular lym-phomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 1995;92:8200–4.
- Janeway CA Jr, Sakato N, Eisen HN. Recognition of immunoglobulin idiotypes by thymus-derived lympho-cytes. Proc Natl Acad Sci USA 1975;72:2357–60.
- Bogen B, Malissen B, Haas W. Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur 7 Immunol 1986;16: 1373–8.
- Campbell MJ, Carroll W, Kon S et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. y Immunol 1987;139:2825–33.
- Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 1996;2:1038–41.
- Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52–8.
- Bendandi M, Gocke CD, Kobrin CB et al. Complete molec-ular remissions induced by patient-specific vaccination plus granulocyte—monocyte colony-stimulating factor against lymphoma. Nat Med 1999;5:1171–7.
- Trojan A, Schultze JL, Witzens M et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 2000;6:667–72.
- Hang S, Witzens M, Krackhardt AM et al. Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte anti-gen-A2 binding residues. Blood 2001;98:2999–3005.